Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACBFF Aurora Cannabis	$4.49 -2.0%	$4.97	$2.20 ▼ $12.53	$4.31B	N/A	4.22 million shs	692,913 shs
ADMA ADMA Biologics	$16.70 -5.1%	$19.29	$10.21 ▼ $25.67	$3.99B	0.43	3.65 million shs	1.35 million shs
CRSP CRISPR Therapeutics	$63.56 +15.4%	$44.08	$30.04 ▼ $66.10	$5.48B	1.82	1.98 million shs	7.00 million shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACBFF Aurora Cannabis	0.00%	-1.10%	-23.25%	+1.13%	-27.70%
ADMA ADMA Biologics	-0.57%	-4.76%	-6.88%	-17.46%	+32.36%
CRSP CRISPR Therapeutics	-0.09%	-6.63%	+27.55%	+45.86%	-8.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	3.8832 of 5 stars	3.7	1.0	0.0	0.0	2.9	2.5	3.1
CRSP CRISPR Therapeutics	2.6882 of 5 stars	3.3	1.0	0.0	0.0	3.3	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACBFF Aurora Cannabis	0.00	N/A	N/A	N/A
ADMA ADMA Biologics	3.33	Buy	$27.67	65.72% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	12.89% Upside

Current Analyst Ratings Breakdown

Latest CU6, CRSP, ADMA, and ACBFF Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/9/2025	CRSP CRISPR Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$56.00 ➝ $42.00
5/8/2025	ADMA ADMA Biologics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Strong-Buy ➝ Strong-Buy	$25.00 ➝ $32.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	$426.45M	9.35	$0.51 per share	32.68	$1.48 per share	11.28
CRSP CRISPR Therapeutics	$37.31M	147.12	N/A	N/A	$22.64 per share	2.81

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACBFF Aurora Cannabis	N/A	$0.12	37.42	∞	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	$197.67M	$0.85	19.66	24.20	N/A	45.01%	47.16%	30.51%	8/6/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)

Latest CU6, CRSP, ADMA, and ACBFF Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	ADMA ADMA Biologics	$0.14	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/7/2025	Q1 2025	ADMA ADMA Biologics	$0.16	$0.14	-$0.02	$0.11	$116.40 million	$114.80 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
ADMA ADMA Biologics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACBFF Aurora Cannabis	N/A	N/A	N/A
ADMA ADMA Biologics	0.22	6.58	3.36
CRSP CRISPR Therapeutics	N/A	15.64	15.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACBFF Aurora Cannabis	N/A
ADMA ADMA Biologics	75.68%
CRSP CRISPR Therapeutics	69.20%

Insider Ownership

Company	Insider Ownership
ACBFF Aurora Cannabis	N/A
ADMA ADMA Biologics	3.50%
CRSP CRISPR Therapeutics	4.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACBFF Aurora Cannabis	1,340	960.96 million	N/A	Not Optionable
ADMA ADMA Biologics	530	238.73 million	230.38 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable

CU6, CRSP, ADMA, and ACBFF Headlines

Recent News About These Companies

CRISPR Therapeutics (CRSP) Surges after Director Buys over $51M Worth of Shares

1 hour ago | tipranks.com

CRISPR Therapeutics (NASDAQ:CRSP) Hits New 52-Week High Following Insider Buying Activity

4 hours ago | marketbeat.com

CRISPR Therapeutics AG (NASDAQ:CRSP) Director Simeon George Purchases 989,812 Shares

5 hours ago | insidertrades.com

Q2 EPS Estimate for CRISPR Therapeutics Increased by Analyst

July 17 at 2:38 AM | americanbankingnews.com

William Blair Issues Optimistic Estimate for CRSP Earnings

July 16 at 6:25 AM | marketbeat.com

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Recommendation of "Moderate Buy" by Analysts

July 16 at 2:21 AM | americanbankingnews.com

CRISPR Therapeutics AG (NASDAQ:CRSP) Given Consensus Recommendation of "Moderate Buy" by Analysts

July 16 at 2:19 AM | marketbeat.com

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

July 15 at 7:01 PM | zacks.com

CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 5.7% - Here's What Happened

July 15 at 2:45 PM | marketbeat.com

Is It Worth Investing in CRISPR Therapeutics (CRSP) Based on Wall Street's Bullish Views?

July 14, 2025 | zacks.com

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

July 14, 2025 | seekingalpha.com

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

July 14, 2025 | seekingalpha.com

Leavell Investment Management Inc. Invests $340,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)

July 13, 2025 | marketbeat.com

12,223 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Acquired by B & T Capital Management DBA Alpha Capital Management

July 12, 2025 | marketbeat.com

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

July 11, 2025 | zacks.com

CRISPR Therapeutics' (CRSP) Buy Rating Reiterated at Needham & Company LLC

July 11, 2025 | americanbankingnews.com

CRISPR Stock Surges in Recent Weeks: What's Going On?

July 10, 2025 | benzinga.com

CRISPR Therapeutics (CRSP) Jumps 9.6% on Biotech Rally

July 10, 2025 | msn.com

CRISPR Therapeutics (CRSP) Moves 9.6% Higher: Will This Strength Last?

July 10, 2025 | zacks.com

CRISPR Therapeutics (NasdaqGM:CRSP) Advances Cardiovascular Programs With Promising Trial Results

July 10, 2025 | finance.yahoo.com

CRISPR Therapeutics Sees Unusually Large Options Volume (NASDAQ:CRSP)

July 9, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CU6, CRSP, ADMA, and ACBFF Company Descriptions

Aurora Cannabis OTCMKTS:ACBFF

$4.49 -0.09 (-1.97%)

As of 07/15/2025

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.

ADMA Biologics NASDAQ:ADMA

$16.70 -0.90 (-5.09%)

As of 01:22 PM Eastern

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.

CRISPR Therapeutics NASDAQ:CRSP

$63.56 +8.47 (+15.37%)

As of 01:22 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time